Self-illuminating liposome-derived <i>in situ</i> triggerable photodynamic therapy combining radionuclide therapy for synergistic treatment of lung cancer.

ABSTRACT: The persistent high prevalence and poor survival outcomes of lung cancer underscore the urgent need for innovative therapeutic modalities. Here, we present a novel multifunctional delivery platform for the synergistic treatment of lung malignancies, combining in situ-triggerable photodynamic therapy (PDT) with radiotherapy. The new platform CLL was developed by loading a new reactive oxygen species (ROS)-triggerable photosensitizer, luminol-conjugated chlorin e6 (Ce6), into liposomes. CLL can be activated through the bioluminescence resonance energy transfer effect under oxidative stress, thereby producing singlet oxygen for targeted tumor treatment without external irradiation. In vitro studies showed significant cytotoxic effects of CLL in both 4T1 and A549 tumor cells. Fur

SUBMITTER: Yuan C 

PROVIDER: S-EPMC12541646 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature